- Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Clinical pharmacology and therapeutics (2014-01-25)
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam, C A Prows, E D Kharasch, T C Skaar
PMID24458010
RÉSUMÉ
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.
MATÉRIAUX
Référence du produit
Marque
Description du produit
Supelco
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Codeine solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Codeine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Morphine sulfate, European Pharmacopoeia (EP) Reference Standard
Codeine, European Pharmacopoeia (EP) Reference Standard